QIBA SPECT Biomarker Committee (BC)
Friday, August 19, 2016, 9 AM (CT)
Draft Call Summary

In attendance:

Yuni Dewaraja, PhD (Co-Chair)   John Dickson, PhD   Anne Smith, PhD   Joe Koudelik
P. David Mozley, MD (Co-Chair)  Robert Miyaoka, PhD   Brian Zimmerman, PhD   Julie Lisiecki
John Seibyl, MD (Co-Chair)      Eric Perlman, MD

RSNA

Moderator: Dr. Mozley

QIBA SPECT BC Poster for RSNA 2016
- Co-Chairs will lead the poster design effort, with collaborative input from team members
- RSNA staff will provide the PowerPoint used to create the PET Amyloid RSNA 2015 print poster, as a template
- Updates will be organized per the format requested by Drs. Jackson and Perlman

QIBA Working Meeting and Breakout Groups at RSNA 2016
A formal announcement will be distributed; however, active QIBA team members are invited to save the date for **Wednesday, November 30th** from ~2:30 – 5:30 pm; Rooms TBD

SPECT Round-6 QIBA Projects Selected
- Two projects have been selected for SPECT:
  1. I-123 DAT Scan Digital Reference Object Development, Dr. Miyaoka
  2. Multi-Center Phantom Study to Characterize Bias and Precision of Quantitative \(^{123}\)I –SPECT, Drs. Dewaraja and Dickson

Profile Edits Reviewed with Assignments
- The latest revised draft of the Profile was reviewed
- Remaining open issues that may require some additional discussion include:
  - Formatting issues
  - DICOM tags (Dr. Dewaraja)
  - Line editing and acceptance of changes and formatting (Dr. Mozley)
  - Use of the term, ‘reference region’ (Dr. Seibyl)
  - The ‘discrimination’ claim has been eliminated; only two claims will be used: a longitudinal claim and a cross-sectional claim
  - Any items that remain uncertain will be placed in the “open issues section”
- The team will work to close as many of these open issues as possible; however, comments received will aid with this effort

Goals include the following:
- Profile draft to be released for Public Comment and Field Testing by September 1st
  - A number of clinical trials will be starting in the near future for Parkinson’s drug testing, and it would be very helpful to partner with iCROs and big pharma at this stage to ask them to test the Profile as well as to provide their input, in order to further refine the Profile for clinical practice
  - To aid with this effort, Dr. Perlman suggested collaboration with the **NBDA**, the National Biomarker Development Alliance
- Dr. Mozley stated that the Technetium (99m Tc) draft Profile is also nearly ready for BC internal review

Nuclear Medicine WebEx Schedule

<table>
<thead>
<tr>
<th>Committees (Fridays, 9 am CT)</th>
<th>SPECT Task Forces: (Tuesdays, 2 pm CT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept 02: FDG-PET BC</td>
<td>Aug 23: Clinical / Literature Review – Dr. Seibyl</td>
</tr>
<tr>
<td>Sept 09: Amyloid BC</td>
<td></td>
</tr>
<tr>
<td>Sept 16: SPECT BC</td>
<td>Sept 06: Image Acquisition /Processing for DaTscan – Dr. Dewaraja</td>
</tr>
<tr>
<td>Sept 23: Combined NM BCs or</td>
<td>Sept 13: Quantitative / Image Analysis – Drs. Miyaoka and Seibyl</td>
</tr>
<tr>
<td>Leadership - TBD</td>
<td>Sept 20: Phantoms / DRO Group – Drs. Dickson and Zimmerman</td>
</tr>
<tr>
<td></td>
<td>Sept 27: Clinical / Literature Review – Dr. Seibyl</td>
</tr>
</tbody>
</table>

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki